Physician profile
Patrick Sporleder
NPI 1922099506
$1,492.43
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $978 · 2020: $284 · 2021: $157 · 2022: $54.03 · 2023: $19.89.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $19.89.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $19.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $254.39 | 2019-2020 | |
| Abbvie INC. | $219.07 | 2019-2022 | |
| Novo Nordisk INC | $203.69 | 2019 | |
| Allergan, INC. | $171.64 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $123.07 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $95.16 | 2019-2020 | |
| Astellas Pharma US INC | $70.39 | 2019-2020 | |
| Supernus Pharmaceuticals, INC. | $65.53 | 2019-2021 | |
| Amarin Pharma, INC. | $52.78 | 2019-2020 | |
| Amgen INC. | $51.67 | 2019 | |
| Lilly USA, LLC | $29.04 | 2019 | |
| Antares Pharma, INC. | $28.57 | 2019-2020 | |
| Glaxosmithkline, LLC. | $26.89 | 2019 | |
| Merck Sharp & Dohme LLC | $24.96 | 2019-2022 | |
| Aytu Biopharma, INC. | $22.68 | 2019 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $19.89 | 2023 | Aristada, Lybalvi |
| Genentech USA, INC. | $19.16 | 2019 | |
| Ironshore Pharmaceuticals INC. | $13.85 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Sporleder listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.